Ypsomed and CamDiab launch mylife Loop on iOS
Ypsomed, together with CamDiab, is launching the iOS version for the mylife CamAPS FX app, which is part of the automated insulin delivery system (AID) mylife Loop.
This allows people with type 1 diabetes to easily and discreetly manage mylife Loop on their iPhones.
The rollout of mylife Loop on iOS will begin on 24 March 2025 in Sweden and will subsequently be expanded to other countries.
"The introduction of the iOS version of the mylife Loop solution is an important step towards the wider availability of AID solutions for the treatment management of type 1 diabetes," explains Sébastien Delarive,Chief Business Officer Diabetes Care at Ypsomed.
Prof. Roman Hovorka, Director CamDiab Ltd, said: "The expansion of the mylife CamAPS FX app to iOS represents a major milestone in making automated insulin delivery more accessible to people with type 1 diabetes.
“Our goal is to provide a seamless, user- friendly experience that empowers individuals to better manage their condition with greater flexibility and convenience.”
Pilot launch in Sweden, followed by a broad rollout
During the pilot phase in Sweden, mylife Loop will initially be available with the FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors from Abbott.
The integration of the Dexcom G6 sensor into the mylife CamAPS FX app will follow. After the successful pilot launch, the rollout of mylife Loop on iOS will continue across Europe followed by Australia and Canada throughout 2025.
Further information and details about the mylife CamAPS FX app can be found at www.mylife-diabetes-care.com/loop
mylife Loop is a modular offer for the treatment of type 1 diabetes. The adaptive mylife CamAPS FX algorithm runs on the personal smartphone and is approved for people with type 1 diabetes from one year of age, depending on the sensor used for continuous glucose monitoring. It is the only algorithm also indicated for pregnant women with type 1 diabetes in Europe and New Zealand.
The mylife CamAPS FX algorithm is combined with the mylife YpsoPump insulin pump and with a sensor for continuous glucose monitoring, either with the FreeStyle Libre 3 or the FreeStyle Libre 3 Plus from Abbott or the Dexcom G6 from Dexcom. Mylife Loop is marketed in most European countries, Canada, Australia and New Zealand.
Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. Ypsomed presents and markets its product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies and hospitals as well as under Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies.
CamDiab Ltd is a digital health and personalised medicine company focused on the design, development, and commercialisation of its world leading, interoperable CamAPS FX closed loop app. The CamAPS FX is designed to use adaptive, self-learning control algorithm, linked to a compatible continuous glucose monitoring device and a compatible insulin pump, to autonomously compute and direct insulin delivery to maintain tight glycaemic control.
For further information, visit www.camdiab.com or follow CamDiab Ltd and its products on Facebook, LinkedIn, and Twitter@CamAPS_FX.